Home > Authors > Soumonty Kanungo

Soumonty Kanungo

  • Now, Dr Reddy's Andhra Pradesh unit under USFDA scanner

    The US Food and Drug Administration (FDA) has issued a Form 483 to Hyderabad-based Dr Reddy's Laboratories where the drug regulator raised inspectional observations at the latter's active pharmaceutical ingredients (API) facility located in the Srikakulam district of Andhra Pradesh. The...

    Thursday, 27 November 2014 - 7:20am
  • Empty capsules lead to Aurobindo drug recall

    Co aker joins long list of Indian pharma companies that have recalled drugs in the US market since January

    Wednesday, 26 November 2014 - 6:25am
  • With Cipla, we are looking at long-term play on foreign turf: Adar Poonawalla

    Leading vaccine manufacturer Serum Institute of India (SII) has recently signed a distribution agreement with pharma major Cipla's European subsidiary Cipla Europe NV to market its paediatric vaccine in the European markets. While the paediatric range includes vaccines for measles-mumps-rubella (...

    Tuesday, 25 November 2014 - 6:35am
  • Government planning to control prices of anti-cancer drugs

    In a bid to make a dozen anti-cancer drugs affordable to the masses, the National Pharmaceutical Pricing Authority (NPPA) has invited comments from the pharmaceutical industry and other stakeholders to bring these drugs under price control. As per the recommendations by Mumbai's Tata Memorial...

    Sunday, 23 November 2014 - 7:00am
  • Cipla in pact with Serum Institute to boost vaccines play

    Cipla, India's second largest drugmaker, said its European subsidiary Cipla Europe NV has signed a distribution agreement with Serum Institute of India (SII) for marketing the latter's vaccines in the European market. While both the companies will start with paediatric vaccines distribution, they...

    Friday, 21 November 2014 - 7:20am
  • Third recall for Sun's Halol unit drug

    US subsidiary of Indian drug major recalls 68,194 bottles of anti-depressant venlafaxine hydrochloride, a third recall for the drug since March

    Tuesday, 18 November 2014 - 6:00am
  • Aurobindo to replace Actavis' drugs with its own to lower cost

    Of the 450 products of Actavis, 200 could be replaced with the company's low-cost high-margin drugs over the next two years

    Tuesday, 11 November 2014 - 6:20am
  • Surprise US FDA nod revocation may cost Ranbaxy $250 million

    The US drug regulator has revoked tentative approvals it gave to Ranbaxy for launching the generic versions of AstraZeneca’s heartburn drug Nexium and Roche’s antiviral drug Valcyte in the US. As a result, the company is expected to face a combined loss of $250 million from the loss of the six...

    Friday, 7 November 2014 - 6:20am
  • Tata hospitality arm Roots Corp to add 100 properties in 3-4 years

    Co's Ginger brand of hotels to consider greenfield, leased rentals and shell conversion options to fuel its expansion drive

    Wednesday, 29 October 2014 - 5:20am
  • Long weekends fuels hotel sector revival

    People clubbing holidays and weekends to go on shorter trips and foreign tourist advance bookings have perked up a 15% growth over last year

    Friday, 24 October 2014 - 6:10am